Insulet Co. (NASDAQ:PODD) Position Increased by ProShare Advisors LLC

ProShare Advisors LLC boosted its holdings in Insulet Co. (NASDAQ:PODD) by 12.3% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 10,614 shares of the medical instruments supplier’s stock after buying an additional 1,159 shares during the quarter. ProShare Advisors LLC’s holdings in Insulet were worth $2,771,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. SBI Securities Co. Ltd. acquired a new position in shares of Insulet in the 4th quarter worth $36,000. Itau Unibanco Holding S.A. purchased a new stake in shares of Insulet during the fourth quarter valued at $42,000. SRS Capital Advisors Inc. boosted its position in shares of Insulet by 43.1% in the 4th quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier’s stock valued at $49,000 after purchasing an additional 56 shares during the period. Assetmark Inc. increased its stake in Insulet by 1,447.1% in the 4th quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier’s stock worth $69,000 after purchasing an additional 246 shares in the last quarter. Finally, Blue Trust Inc. increased its stake in Insulet by 117.3% in the 4th quarter. Blue Trust Inc. now owns 276 shares of the medical instruments supplier’s stock worth $72,000 after purchasing an additional 149 shares in the last quarter.

Insulet Price Performance

NASDAQ PODD opened at $327.47 on Wednesday. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. The stock has a market capitalization of $23.05 billion, a PE ratio of 56.56, a price-to-earnings-growth ratio of 3.62 and a beta of 1.26. Insulet Co. has a 12-month low of $170.67 and a 12-month high of $329.00. The company has a 50 day moving average price of $267.35 and a two-hundred day moving average price of $267.99.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.81 by $0.21. The business had revenue of $569.00 million during the quarter, compared to analyst estimates of $543.20 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%. Insulet’s quarterly revenue was up 28.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.73 EPS. As a group, equities analysts predict that Insulet Co. will post 3.92 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have commented on PODD shares. Barclays upped their price objective on shares of Insulet from $234.00 to $266.00 and gave the company an “equal weight” rating in a research note on Wednesday, April 30th. StockNews.com lowered shares of Insulet from a “buy” rating to a “hold” rating in a report on Tuesday, March 4th. Stifel Nicolaus upped their price target on shares of Insulet from $245.00 to $293.00 and gave the company a “hold” rating in a research report on Friday, February 21st. Wells Fargo & Company set a $322.00 price objective on shares of Insulet in a research report on Monday, April 28th. Finally, Piper Sandler boosted their target price on shares of Insulet from $285.00 to $310.00 and gave the company an “overweight” rating in a research note on Friday, February 21st. Four investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to data from MarketBeat.com, Insulet currently has a consensus rating of “Moderate Buy” and a consensus target price of $306.53.

Insider Activity

In other news, SVP John W. Kapples sold 5,278 shares of the firm’s stock in a transaction dated Wednesday, May 14th. The stock was sold at an average price of $318.47, for a total value of $1,680,884.66. Following the sale, the senior vice president now directly owns 23,180 shares of the company’s stock, valued at approximately $7,382,134.60. This trade represents a 18.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Wayne A.I. Frederick sold 1,825 shares of the business’s stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total value of $501,875.00. Following the transaction, the director now directly owns 3,231 shares of the company’s stock, valued at $888,525. This represents a 36.10% decrease in their position. The disclosure for this sale can be found here. 0.39% of the stock is currently owned by insiders.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.